BMS

CheckMate 214

NCT02231749

McG1224

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Nivolumab + Ipilimumab

Treatment Arms

o Experimental: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg

o Active Comparator: Arm B: Sunitinib 50 mg